刘晓霞 (副研究员)

研究方向:肿瘤微环境代谢重编程与结直肠癌恶性进展关系的研究
教育经历:
2005年9月—2009年6月,湖南中医药大学 药学学士
2009年9月—2014年6月,南方医科大学药理学博士(硕博连读)
研究经历:
2014年7月—2015年7月,助理研究员,南方医科大学珠江医院新药研发中心 
2015年8月-2018年8月,博士后,中山大学肿瘤防治中心实验研究部
2018年9月-2021年12月,特聘副研究员, 中山大学附属第六医院
2022年1月-至今,副研究员, 中山大学附属第六医院 

代表性论文代表性项目荣誉
(1) Xiaoxia Liu#, Yanyu Zhang#, Wenhua Lu# Yi Han#, Jing Yang, Weiye Jiang, Xin You, Yao Luo, Shijun Wen, Yumin Hu and Peng Huang. Mitochondrial TXNRD3 confers drug resistance via redox-mediated mechanism and is a potential therapeutic target in vivo. Redox Biol. 2020 Jul 23;36:101652. 
(2) Shaoyong Peng, Yingjie Li, Meijin Huang, Guannan Tang,Yumo Xie, Daici Chen, Yumin Hu, Tiantian Yu, Jian Cai, Zixu Yuan, Huaiming Wang, Hui Wang, Yanxin Luo, Xiaoxia Liu*. Metabolomics reveals that CAF-derived lipids promote colorectal cancer peritoneal metastasis by enhancing membrane fluidity. INT J BIOL SCI.2022; 18(5): 1912-1932. 
(3) Shaoyong Peng#, Daici Chen#, Jian Cai#, Zixu Yuan, Binjie Huang, Yichen Li, Huaiming Wang, Qianxin Luo, Yingyi Kuang, Wenfeng Liang, Zhihang Liu, Qian Wang, Yanmei Cui, Hui Wang*, Xiaoxia Liu*. Enhancing cancer-associated fibroblasts fatty acid catabolism within a metabolically challenging tumor microenvironment drives colon cancer peritoneal metastasis. Mol Oncol. 2021 May;15(5):1391-1411. doi: 10.1002/1878-0261.12917.
(4) Xiaoxia Liu#; Yanyu Zhang#; Yi Han#; Wenhua Lu; Jing Yang; Jingyu Tian; Peng Sun; Tiantian Yu; Yumin Hu; Hui Zhang*; Peng Huang*; Panpan Liu*; Overexpression of GLT1D1 induces immunosuppression through glycosylation of PD‐L1 and predicts poor prognosis in B-cell lymphoma. Molecular Oncology. 2020 May;14(5):1028-1044. 
(5) Liu, Xiaoxia#,Wang, Wei#,Samarsky, Dmitry,Liu, Li,Xu, Qian,Zhang, Wenqing,Zhu, Guangzu,Wu, Ping,Zuo, Xialin,Deng, Houliang,Zhang, Jingjing,Wu, Zhuomin,Chen, Xiaohui,Zhao, Lingfeng,Qiu, Zhiyong,Zhang, Zhongyi,Zeng, Qiyi,Yang, Wei,Zhang, Biliang(*),Ji, Aimin(*) ,Tumor-targeted in vivo gene silencing via systemic delivery of cRGD-conjugated siRNA. Nucleic Acids Research,2014,42(18):11805-11817 
(6) Lang Xie, Renli Huang, Hongyun Huang, Xiaoxia Liu*, Jinlong Yu*. Transcriptomics and Metabolomics identify drug resistance of dormant cell in colorectal Cancer. Frontiers in Pharmacology, 2022 Apr 8;13:879751. doi: 10.3389/fphar.2022.879751.
(7) Li Wang, Qian Yang, Shaoyong Peng, Xiaoxia Liu*. The combination of the glycolysis inhibitor 2-DG and sorafenib can be effective against sorafenib-tolerant persister cancer cells. Onco Targets Ther. 2019 Jul 8;12:5359-5373. doi: 10.2147/OTT.S212465. 
(8) Bohong Cen, Wenjie Liao, Zhen Wang, Linyuan Gao, Yuanyi Wei, Wen Huang, Shuai He, Xiaoxia Liu*, Xinghua Pan*, Aimin Ji*. Gelofusine  Attenuates Tubulointerstitial Injury Induced by cRGD-Conjugated siRNA by Regulating the TLR3 Signaling Pathway. Mol Ther Nucleic Acids. 2018 Jun 1;11:300-311.  
(9) Xiaoxia Liu*, Li Wang, Weiye Jiang, Wenhua Lu, Jing Yang, Wenbiao Yang. B cell lymphoma with different metabolic characteristics show distinct sensitivities to metabolic inhibitors. J CANCER. 2018 Apr 12;9(9):1582-1591. 
(10) Chen, Shan(#),Liu, Xiaoxia(#),Gong, Wenfei,Yang, Huan,Luo, Daofei,Zuo, Xialin,Li, Wenshi,Wu, Ping,Liu, Li,Xu, Qian,Ji, Aimin(*),Combination therapy with VEGFR2 and EGFR siRNA enhances the antitumor effect of cisplatin in non-small cell lung cancer xenografts.,Oncology Reports,2013,29(1):260-268   
(11) Liu, Xiaoxia,Liu, Li,Xu, Qian,Wu, Ping,Zuo, Xialin,Ji, Aimin(*),MicroRNA as a novel drug target for cancer therapy,Expert Opinion ON Biological Therapy,2012,12(5):573-580